10,000 patients to reveal how safe midline catheters really are
NCT ID NCT07677696
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study follows 10,000 adults receiving a midline catheter for intravenous therapy lasting 1 to 4 weeks as part of routine care. Researchers track complications like infection, blockage, or blood clots to see how well these devices perform in everyday hospital settings. The goal is to provide clear evidence on whether midline catheters are a safe and effective choice for short-term IV access.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- midline catheter
- What this could lead to
- If successful, this study could confirm that midline catheters are a safe and effective option for short-term intravenous therapy, potentially reducing complications from other vascular access devices.
- What could go wrong
- As an observational study, it cannot prove cause and effect. Results may be influenced by differences in patient care or data collection across hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AND EFFECTIVENESS OF MIDLINE CATHETERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zibo Central Hospital
RECRUITINGZibo, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.